• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Volume Volume 5 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Afifi, M., Shamsya, A., AbdoHaider, D., Tahoun, M., Hanafy, M. (2023). THE ROLE OF SERUM VISFATIN IN THE DIAGNOSIS OF ACTIVE INFLAMMATORY BOWEL DISEASE. ALEXMED ePosters, 5(3), 62-63. doi: 10.21608/alexpo.2023.238579.1699
Mohamed Tamer Ahmed Mahmoud Afifi; Ayman Mohamed Shamsya; Doaa AbdoMohamed AbdoHaider; Mona Moustafa Tahoun; Mayar Ahmed Mohamed Hanafy. "THE ROLE OF SERUM VISFATIN IN THE DIAGNOSIS OF ACTIVE INFLAMMATORY BOWEL DISEASE". ALEXMED ePosters, 5, 3, 2023, 62-63. doi: 10.21608/alexpo.2023.238579.1699
Afifi, M., Shamsya, A., AbdoHaider, D., Tahoun, M., Hanafy, M. (2023). 'THE ROLE OF SERUM VISFATIN IN THE DIAGNOSIS OF ACTIVE INFLAMMATORY BOWEL DISEASE', ALEXMED ePosters, 5(3), pp. 62-63. doi: 10.21608/alexpo.2023.238579.1699
Afifi, M., Shamsya, A., AbdoHaider, D., Tahoun, M., Hanafy, M. THE ROLE OF SERUM VISFATIN IN THE DIAGNOSIS OF ACTIVE INFLAMMATORY BOWEL DISEASE. ALEXMED ePosters, 2023; 5(3): 62-63. doi: 10.21608/alexpo.2023.238579.1699

THE ROLE OF SERUM VISFATIN IN THE DIAGNOSIS OF ACTIVE INFLAMMATORY BOWEL DISEASE

Article 1, Volume 5, Issue 3, September 2023, Page 62-63  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2023.238579.1699
View on SCiNiTO View on SCiNiTO
Authors
Mohamed Tamer Ahmed Mahmoud Afifi1; Ayman Mohamed Shamsya2; Doaa AbdoMohamed AbdoHaider1; Mona Moustafa Tahoun3; Mayar Ahmed Mohamed Hanafy email 1
1Department of Internal Medicine, Faculty of Medicine, Alexandria University
2Department of Internal Medicine, Faculty of Medicine, University of Alexandria
3Department of Clinical and Chemical Pathology, Faculty of Medicine University of Alexandria.
Abstract
Inflammatory bowel disease (IBD) is characterized by repetitive episodes of inflammation of the gastrointestinal tract, IBD encompasses two main types: Ulcerative colitis (UC) and Crohn disease (CD) that are differentiated by their location and depth of involvement in the bowel wall, The most important determinant of the clinical course of IBD is the balance between proinflammatory, anti-inflammatory, and immunomodulating factors. Inflammatory reactions localized in the bowel wall may penetrate the surrounding visceral adipose tissue,evidence for submucosal fat deposition in the bowel is observed in CD and UC patients. The anatomic proximity of the bowel and visceral fat favors the activation of adipocytes. One of the recently reported adipokines involved in IBD is visfatin. It increases the epithelial expression of tumor necrosis factor alpha (TNF-α), interleukin (IL)-l, IL-6, and adhesion molecules. It is a noninvasive, easily measured, and an inexpensive marker to diagnose and monitor activity and severity in IBD.
AIM OF THE WORK:
The aim of this study was to determine the serum concentrations of visfatin in IBD patients, to evaluate its role in the diagnosis of IBD and correlate it with disease activity and colonoscopic findings.
Keywords
Inflammatory bowel disease (IBD); Ulcerative colitis (UC); Crohn disease (CD)
Supplementary Files
download 1699 12 (3).pdf
Statistics
Article View: 139
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.